scispace - formally typeset
G

Gordon H. Williams

Researcher at Brigham and Women's Hospital

Publications -  563
Citations -  39948

Gordon H. Williams is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Angiotensin II & Aldosterone. The author has an hindex of 88, co-authored 559 publications receiving 38048 citations. Previous affiliations of Gordon H. Williams include University of Sydney & University of Michigan.

Papers
More filters
Journal ArticleDOI

Activation of the Mineralocorticoid Receptor Increases Striatin Levels

TL;DR: Evidence is provided that increased striatin levels is a component of MR activation in the vasculature and suggest that regulation of striatin by ALDO may modulate estrogen's nongenomic effects.
Journal ArticleDOI

Variability in time delay between two models of pulse oximeters for deriving the photoplethysmographic signals.

TL;DR: Using raw PPG signals obtained directly from these oximeters for timing-related measurements warrants further investigations, and Documented evidence suggests that 1 ms variation in PTT is equivalent to 1 mmHg change in blood pressure.
Journal ArticleDOI

The calcium channel blocker diltiazem lowers serum parathyroid hormone levels in vivo and in vitro.

TL;DR: Diltiazem lowered PTH levels in vivo and in vitro, perhaps acting as a Ca2+ channel agonist in the parathyroid cell and inhibiting PTH release through a rise in the cytosolic Ca2- concentration.
Journal ArticleDOI

Dissociation of Hyperglycemia from Altered Vascular Contraction and Relaxation Mechanisms in Caveolin-1 Null Mice

TL;DR: In this paper, the authors showed that metformin inhibits both vascular contraction and NO-cGMP-dependent relaxation but does not affect BP or blood glucose in cav-1−/− mice, suggesting dissociation of hyperglycemia from altered vascular function in Cav-1 deficiency states.
Journal Article

Use of calcium channel blockers in hypertension.

TL;DR: During the past 20 years the number of subclasses of calcium channel blockers has increased from one to four, and three classes have only a single clinically approved compound: verapamil, diltiazem, and mibefradil.